Victory Capital Management Inc. Has $5.68 Million Position in BioLife Solutions, Inc. (NASDAQ:BLFS)

Victory Capital Management Inc. lifted its holdings in shares of BioLife Solutions, Inc. (NASDAQ:BLFS) by 422.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 218,962 shares of the medical equipment provider’s stock after purchasing an additional 177,028 shares during the quarter. Victory Capital Management Inc.’s holdings in BioLife Solutions were worth $5,684,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Rockefeller Capital Management L.P. lifted its position in shares of BioLife Solutions by 81.3% during the 3rd quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after buying an additional 262,504 shares during the last quarter. Mutual of America Capital Management LLC increased its position in BioLife Solutions by 31.2% during the 4th quarter. Mutual of America Capital Management LLC now owns 521,937 shares of the medical equipment provider’s stock valued at $13,549,000 after purchasing an additional 124,165 shares during the period. State Street Corp lifted its holdings in BioLife Solutions by 7.3% in the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock valued at $35,364,000 after buying an additional 95,788 shares during the period. Stephens Investment Management Group LLC boosted its position in shares of BioLife Solutions by 16.7% during the 4th quarter. Stephens Investment Management Group LLC now owns 495,970 shares of the medical equipment provider’s stock valued at $12,875,000 after purchasing an additional 70,875 shares in the last quarter. Finally, Peregrine Capital Management LLC increased its stake in shares of BioLife Solutions by 18.1% in the 4th quarter. Peregrine Capital Management LLC now owns 352,205 shares of the medical equipment provider’s stock valued at $9,143,000 after acquiring an additional 54,100 shares in the last quarter. Institutional investors own 93.24% of the company’s stock.

Insider Buying and Selling at BioLife Solutions

In other news, insider Sarah Aebersold sold 1,091 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $25.00, for a total value of $27,275.00. Following the transaction, the insider now owns 58,816 shares in the company, valued at approximately $1,470,400. This trade represents a 1.82 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Troy Wichterman sold 987 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the sale, the chief financial officer now directly owns 121,779 shares in the company, valued at $3,290,468.58. The trade was a 0.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 20,394 shares of company stock valued at $533,124 in the last 90 days. Corporate insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

BLFS has been the subject of several research reports. Northland Securities raised their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday, January 8th. KeyCorp boosted their target price on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research report on Friday, December 13th. Benchmark reiterated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, HC Wainwright upped their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Thursday, March 6th. One equities research analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, BioLife Solutions has a consensus rating of “Moderate Buy” and a consensus target price of $29.86.

BioLife Solutions Stock Down 0.2 %

BLFS opened at $25.00 on Friday. The company has a 50 day moving average of $26.59 and a 200 day moving average of $25.49. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. BioLife Solutions, Inc. has a 12 month low of $14.84 and a 12 month high of $29.55. The company has a market cap of $1.18 billion, a PE ratio of -23.58 and a beta of 2.04.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32. The company had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. During the same period last year, the business earned ($0.21) earnings per share. On average, sell-side analysts expect that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

BioLife Solutions Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.